We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
- Authors
Wang, Bei; Deng, Rong; Hennig, Stefanie; Badovinac Crnjevic, Tanja; Kaewphluk, Monika; Kågedal, Matts; Quartino, Angelica L.; Girish, Sandhya; Li, Chunze; Kirschbrown, Whitney P.
- Abstract
In the Results section, Pertuzumab population pharmacokinetic analysis, Page 5, Paragraph 1, Line 2: " I V i SB p sb " should be replaced with " I V i SB I p i sb ", i.e., ' SB I p i sb ' in italics. In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 21: " I V i SB c sb " should be replaced with " I V i SB I c i sb ", i.e., ' SB I c i sb ' in italics. In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 20: "× (1.123if" should be replaced with "× (1.123 if", i.e., a space inserted after the '1.123'.
- Subjects
HER2 positive breast cancer; SUBCUTANEOUS injections; TRASTUZUMAB; PACLITAXEL; PHARMACOKINETICS; CANCER chemotherapy
- Publication
Cancer Chemotherapy & Pharmacology, 2022, Vol 89, Issue 4, p571
- ISSN
0344-5704
- Publication type
Correction Notice
- DOI
10.1007/s00280-021-04342-x